Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 – 2018)

References

• Quigley HA. Glaucoma. Lancet. 2011;377(9774):1367–1377.
   PubMed Web of Science ®Google Scholar
• Martin E, Patrianakos T, Giovingo M. Medication induced glaucoma. Dis Mon. 2017;63(2):54–57.
   PubMed Web of Science ®Google Scholar
• Sharif NA. Ocular hypertension and glaucoma: a review and current perspectives. Int J Ophthalmol Visual Sci. 2017;2(3):22–36.
   Google Scholar
• Hong CJ, Trope GE. Glaucoma. CMAJ. 2015;187(12):E398–9.
   PubMed Web of Science ®Google Scholar
• Foster PJ, Buhrmann R, Quigley HA, et al. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002;86(2):238–242.
   PubMed Web of Science ®Google Scholar
• Fautsch MP, Johnson DH. Aqueous humor outflow: what do we know? Where will it lead us? Invest Ophthalmol Vis Sci. 2006;47:4181–4187.
   PubMed Web of Science ®Google Scholar
• Mantravadi AV, Vadhar N. Glaucoma. Prim Care. 2015;42(3):437–449.
   PubMed Web of Science ®Google Scholar
• Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005;62(7):691–699.
   PubMed Web of Science ®Google Scholar
• Kwon YH, Fingert JH, Kuehn MH, et al. Primary open-angle glaucoma. N Engl J Med. 2009;360(11):1113–1124.
   PubMed Web of Science ®Google Scholar
• Hyams S. Angle-closure glaucoma: a comprehensive review of primary and secondary angle-closure glaucoma. Amsterdam: Kugler & Ghedini; 1990.
   Google Scholar
• European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona: Dogma; 2008.
   Google Scholar
• Arranz-Marquez E, Teus MA. Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008;7(6):801–808.
   PubMed Web of Science ®Google Scholar
• Doucette LP, Walter MA. Prostaglandins in the eye: function, expression, and roles in glaucoma. Ophthalmic Genet. 2017;38(2):108–116.
   PubMed Web of Science ®Google Scholar
• Klimko P, Sharif NA. Discovery, characterization and clinical utility of prostaglandin agonists for treatment of glaucoma. Br J Pharmacol. 2019;176:1051–1058.
   PubMed Web of Science ®Google Scholar
• Goh Y, Nakajima M, Azuma I, et al. Prostaglandin D2 reduces intraocular pressure. Br J Ophthalmol. 1988;72(6):461–464.
   PubMed Web of Science ®Google Scholar
• Goh Y, Nakajima M, Azuma I, et al. Effects of prostaglandin D2 and its analogues on intraocular pressure in rabbits. Jpn J Ophthalmol. 1988;32(4):471–480.
   PubMed Web of Science ®Google Scholar
• Sharif NA, Williams GW, Crider JY, et al. Molecular pharmacology of the ocular hypotensive DP/EP2 class prostaglandin AL-6598 and localization of DP and EP2 receptor sites in human eyes. J Ocular Pharmacol Ther. 2004;20:489–508.
   PubMed Web of Science ®Google Scholar
• Schlotzer-Schrehardt U, Zenkel M, Nusing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43(5):1475–1487.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Geoghegan TE, Patil RV, et al. Detection of EP2, EP4, and FP receptors in human ciliary epithelial and ciliary muscle cells. Biochem Pharmacol. 1997;53(9):1249–1255.
   PubMed Web of Science ®Google Scholar
• Ota T, Aihara M, Saeki T, et al. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006;47(8):3395–3399.
   PubMed Web of Science ®Google Scholar
• Crider JY, Sharif NA. Functional pharmacological evidence for EP2 and EP4 prostanoid receptors in immortalized human trabecular meshwork and N-PCE cells. J Ocular Pharmacol Ther. 2001;17:35–46.
   PubMed Web of Science ®Google Scholar
• Stamer WD, Piwnica D, Jolas T, et al. Cellular basis for bimatoprost effects on human conventional outflow. Invest Ophthalmol Vis Sci. 2010;51(10):5176–5181.
   PubMed Web of Science ®Google Scholar
• Lee PY, Shao H, Xu LA, et al. The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects. Invest Ophthalmol Vis Sci. 1988;29(10):1474–1477.
   PubMed Web of Science ®Google Scholar
• Camras CB, Siebold EC, Lustgarten JS, et al. Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology. 1989;96(9):1329–1336.
   PubMed Web of Science ®Google Scholar
• Nilsson SFE, Drecoll E, Lütjen-Drecoll E, et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey.invest. Ophthalmol Visual Sci. 2006;47:4042−4049.
   PubMed Web of Science ®Google Scholar
• Bahler CK, Howell KG, Hann CR, et al. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol. 2008;145:114–119.
   PubMed Web of Science ®Google Scholar
• Nilsson SFE, Samuelsson M, Bill A, et al. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2, -l-isopropylesterin the cynomolgus monkey. Exp Eye Res. 1989;48:707–716.
   PubMed Web of Science ®Google Scholar
• Poyer JF, Millar C, Kaufman PL, et al. Effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol. 1995;36:2461–2465.
   Google Scholar
• Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandin action on ciliary smooth muscle extracellularmatrix metabolism: implications for uveoscleral outflow. Surv Ophthalmol. 1997;41:S53–9.
   PubMed Web of Science ®Google Scholar
• Wan Z, Woodward DF, Cornell CL, et al. Bimatoprost, prostamide activity, and conventional drainage. Investig Ophthal Vis Sci. 2007;48:4107–4115.
   PubMed Web of Science ®Google Scholar
• Wang JW, Woodward DF, Stamer WD. Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow. Invest Ophthalmol Vis Sci. 2013;54:4782–4790.
   PubMed Web of Science ®Google Scholar
• Maxey KM, Stanton ML Internal 1,15-lactones of fluprostenol and related prostaglandin F2A analogs and their use in the treatment of glaucoma and intraocular hypertension. US0146821. 2008
   Google Scholar
• Woodward DF, Burk RM Novel prostamides for the treatment of glaucoma and related diseases. US0112058. 2007
   Google Scholar
• Ellis D, Scheibler L, Sharif N Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension. WO2016061370. 2016
   Google Scholar
• Ongini E, Benedini F, Chiroli V, et al. Prostaglandin derivatives. EP3002277. 2016
   Google Scholar
• Wang T, Tsang SH, Chen J. Two pathways of rod photoreceptor cell death induced by elevated cGMP. Hum Mol Genet. 2017;26(12):2299–2306.
   PubMed Web of Science ®Google Scholar
• Vittitow JL, Cavet ME Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma. WO2018087092. 2018
   Google Scholar
• Almirante N, Storoni L, Bastia E, et al. Combinations of prostaglandins and nitric oxide donors. US20170354634. 2017.
   Google Scholar
• Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6(1):45–52.
   PubMed Web of Science ®Google Scholar
• Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53:S93–105.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem. 2014;75:349–359.
   PubMedGoogle Scholar
• Masini E, Carta F, Scozzafava A, et al. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(6):705–716.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007–2011. Expert Opin Ther Pat. 2012;22(1):79–88.
   PubMed Web of Science ®Google Scholar
• Kopczynski C, Lin CW, Sturdivant JM, et al. Combination therapy. US20180344724. 2018.
   Google Scholar
• Moura-Coelho N, Tavares Ferreira J, Bruxelas CP, et al. Rho kinase inhibitors – a review on the physiology and clinical use in ophthalmology. Graefes Arch Clin Exp Ophthalmol. 2019;257(6):1101–1117.
   PubMed Web of Science ®Google Scholar
• Savinainen A, Shawer M Compounds and compositions for the treatment of ophthalmic disorders. US20180215788. 2018.
   Google Scholar
• Kotani M, Tanaka I, Ogawa Y, et al. Structural organization of the human prostaglandin EP3 receptor subtype gene (PTGER3). Genomics. 1997;40:425–434.
   PubMed Web of Science ®Google Scholar
• Saeki T, Ota T, Aihara M, et al. Effects of prostanoid EP agonists on mouse intraocular pressure. Invest Ophthalmol Vis Sci. 2009;50:2201–2208.
   PubMed Web of Science ®Google Scholar
• Bhattacherjee P, Williams BS, Paterson CA. Responses of intraocular pressure and the pupil of feline eyes to prostaglandin EP1 and FP receptor agonists. Invest Ophthalmol Vis Sci. 1999;40:3047–3053.
   PubMed Web of Science ®Google Scholar
• Krauss AH, Chen J, Kharlamb A, et al. A selective Prostanoid EP2 receptor agonist (butaprost) normalizes glaucom-atous monkey intraocular pressure invest. Ophthalmol Visual Sci. 2002;43:4107−8.
   Web of Science ®Google Scholar
• Kirihara T, Shimazaki A, Sharif NA prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound. US20180200239A1. 2018.
   Google Scholar
• Kirihara T, Taniguchi T, Yamamura K, et al. Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 recep-tor agonist, as an ocular hypotensive agent. Invest Ophthalmol Vis Sci. 2018;59(1):145–153.
   PubMed Web of Science ®Google Scholar
• Impagnatiello F, Bastia E, Almirante N, et al. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. Br J Pharmacol. 2019;176(8):1079–1089.
   PubMed Web of Science ®Google Scholar
• Ferro Desideri L, Cutolo CA, Barra F, et al. Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension. Drugs Today (Barc). 2019;55(6):377–384.
   PubMed Web of Science ®Google Scholar
• Rollín R, Mediero A, Roldán-Pallarés M, et al. Natriuretic peptide system in the human retina. Mol Vis. 2004;10:15–22.
   PubMed Web of Science ®Google Scholar
• Goh Y, Nakajima M. Stimulatory effects of prostaglandin D2 analogues on adenylate cyclase in rabbit irisciliary body membrane fractions. Exp Eye Res. 1990;51:585–590.
   PubMed Web of Science ®Google Scholar
• Ota T, Aihara M, Saeki T, et al. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006;47:3395–3399.
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Hennes EA, Bendel MA, et al. Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. Ocul Pharmacol Ther. 2009;25:1–8.
   PubMed Web of Science ®Google Scholar
• Yamane S, Karakawa T, Nakayama S, et al. IOP-lowering effect of ONO-9054 – a novel dual agonist of prostanoid EP3 and FP receptors – in monkeys. Invest Ophthalmol Vis Sci. 2015;56:2547–2552.
   PubMed Web of Science ®Google Scholar
• Markovič T, Jakopin Ž, Dolenc MS, et al. Structural features of subtype-selective EP receptor modulators. Drug Discov Today. 2017;22(1):57–71.
   PubMed Web of Science ®Google Scholar
• Billot X, Han Y, Young RN. EP4 receptor agonist, compositions and methods thereof. US20130317013. 2013.
   Google Scholar
• Borriello M, Pucci S, Stasi LP, et al. Cyclic amine derivative sas EP4 receptor agonists. US20140243373. 2014.
   Google Scholar
• Donde Y, Nguyen JH Therapeutic prostaglandin receptor agonists. US20150329518. 2015.
   Google Scholar
• Old DW Therapeutic substituted pyrroles. US20150336940. 2015.
   Google Scholar
• Nakajima M, Goh Y, Azuma I, et al. Effects of prostaglandin D2 and its analogue, BW245C, on intraocular pressure in humans. Graefes Arch Clin Exp Ophthalmol. 1991;229(5):411–413.
   PubMed Web of Science ®Google Scholar
• Toris CB, Zhan GL, Feilmeier MR, et al. Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma. J Ocul Pharmacol Ther. 2006;22:86–92.
   PubMed Web of Science ®Google Scholar
• Sharif NA, Williams GW, Crider JY, et al. Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes. J Ocul Pharmacol Ther. 2004;20:489–508.
   PubMed Web of Science ®Google Scholar
• Woodward DF, Nilsson SF, Toris CB, et al. Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. Invest Ophthalmol Vis Sci. 2009;50:3320–3328.
   PubMed Web of Science ®Google Scholar